Tiziana Study Results from Intranasal Anti-CD3 Foralumab in MS

 - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -

- Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado -

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a study related to its lead candidate, foralumab, was highlighted in Neurology Today^®, the official news source of the American Academy of Neurology (AAN), in an article titled, “Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand.”

The study is authored by Tarun Singhal, M.B.B.S., M.D., Director, PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, and Associate Professor of Neurology at Harvard Medical School, and shows that foralumab, a fully human anti-CD3 monoclonal-antibody, attenuates microglial activation in non-active secondary progressive multiple sclerosis (na-SPMS) patients with progression independent of relapse (PIRA). A systemic review published in JAMA Neurology^[1] in October 2023 found that PIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional multiple sclerosis (MS) phenotypes.

https://www.biospace.com/article/releases/tiziana-life-sciences-announces-study-results-from-intranasal-anti-cd3-foralumab-in-multiple-sclerosis-patients-with-pira-highlighted-in-neurology-today-/